Abstract: Disclosed is a biarylamide compound as a Pan-RAF kinase inhibitor, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.

Abstract: A tetracyclic compound as a Cdc7 inhibitor. Specifically disclosed is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

Abstract: A kitchen faucet with a garbage disposer comprises a faucet unit, the garbage disposer, and a sensing unit. The faucet unit comprises a water outlet passage unit, and the water outlet passage unit is disposed with a first control valve configured to control an opening and a closing of the water outlet passage unit. The garbage disposer is located under a water outlet of the water outlet passage unit of the faucet unit. The sensing unit is disposed on the faucet unit and is configured to generate a normal water outlet instruction and a garbage disposal instruction respectively according to a long sensing distance and a short sensing distance. The first control valve is configured to be opened and closed through the normal water outlet instruction, and the first control valve and the garbage disposer are respectively configured to be opened and closed through the garbage disposal instruction.

Abstract: Disclosed are a crystal form of a c-MET inhibitor and a salt form thereof and a preparation method therefor. Specifically involved are the compound as shown in formula (I), and a salt form and a crystal form thereof, and also included is the use of the crystal form and the salt form in the preparation of medicines for treating cancers.

Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pyrimidine compound acting on an EGFR exon 20 insertion mutation and an ERBB2 exon 20 insertion mutation or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses new azaindole pyrazole compounds as CDK9 inhibitors, in particular, compounds as represented by formula (I), pharmaceutically acceptable salts and isomers thereof, and the use of compounds represented by formula (I), pharmaceutically acceptable salts and isomers thereof, and the pharmaceutical composition containing them in the preparation of cancer drugs.

Abstract: A crystal form and a salt form of a uracil compound acting as a c-MET/AXL inhibitor and a preparation method therefor, specifically relating to the crystal form and the salt form of the compound shown in formula (I), and also comprising an application of the crystal form and the salt form in the preparation of drugs for the treatment of tumours.

Abstract: A new class of tetracyclic compounds acting as Cdc7 inhibitors; specifically disclosed are a compound represented by formula (I), isomers thereof, or pharmaceutically acceptable salts thereof.

Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

Abstract: Disclosed are a crystal form of an EGFR inhibitor and a preparation method thereof. Further disclosed is an application of the crystal form in preparing a drug for treating non-small cell lung cancer, especially an application in preparing a drug for treating non-small cell lung cancer with brain metastases.

Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.

Abstract: Provided are a crystallization of an SMAC mimic used as an IAP inhibitor and a preparation method thereof; also comprised is the use of said crystallization in the preparation of a drug for treating cancer benefiting from cIAP1 inhibition. The compound of formula (I) has high crystallization stability and low hygroscopicity, and has advantages in terms of physical properties, safety, and metabolic stability, and has high drug value.

Abstract: The present invention relates to a combination of a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof which are used as an IAP inhibitor, and an immune checkpoint inhibitor; and use of the combination in the preparation of a cancer treatment drug.

Abstract: Provided are a salt of an EGFR inhibitor, a crystal form thereof and a preparation method therefor, and an application of the salt and the crystal form in the preparation of a treatment for non-small cell lung cancer. The salt has a structure as shown in formula (II).

Abstract: Disclosed are a group of 5-(4-pyridyloxy)pyrazole compounds serving as a TGF-?R1 kinase inhibitor, and applications of same in preparing a TGF-?R1 kinase inhibitor medicament. Specifically disclosed are the compounds as represented by formula (I), a pharmaceutically acceptable salt or an isomer thereof.

Abstract: A pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and a preparation method therefor and application thereof. The pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof is simple to synthesize, easy to prepare, rich in raw materials for synthesis, and has an inhibitory effect on a plurality of tyrosine kinases, especially has higher selective inhibitory activity against KDR (VEGFR2), and FLT3 and its mutants, and can avoid toxic side effects caused by inhibiting KDR.

Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.

Abstract: Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.